faricimab
Marketed as VABYSMO.
FDA approval history
| FDA ID | Brand | Approval date | Manufacturer |
|---|---|---|---|
| BLA761235 | VABYSMO | 2022-01-28 | GENENTECH INC |
Manufacturers
GENENTECH INC
Common denial patterns
- Step therapy requiring aflibercept or bevacizumab first
- Quantity limit on injections per eye
- Off-label use beyond AMD/DME indication
Specific notes
Brand: Vabysmo. First bispecific antibody for retinal disease — targets both VEGF-A and Ang-2. FDA-approved for wet AMD, DME (2022), and macular edema following RVO (October 2023). Up to 16-week dosing intervals supported.
Genentech Access Solutions: https://www.vabysmo-access.com
Frequently asked questions
Why does insurance commonly deny faricimab?
Step therapy requiring aflibercept or bevacizumab first; Quantity limit on injections per eye; Off-label use beyond AMD/DME indication.
When was faricimab FDA approved?
Earliest FDA approval on record: 2022-01-28.
What brand names are sold as faricimab?
VABYSMO.
Is there a patient assistance program for faricimab?
Yes — Genentech Access Solutions at https://www.vabysmo-access.com.
What's specific to faricimab?
Brand: Vabysmo. First bispecific antibody for retinal disease — targets both VEGF-A and Ang-2. FDA-approved for wet AMD, DME (2022), and macular edema following RVO (October 2023). Up to 16-week dosing intervals supported.
Sources
Appeal a faricimab denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com